Key Highlights

  • Phase 2 Binge Eating Disorder study delivers 100% of patients achieving clinically meaningful improvement and 50% achieving complete remission at both four- and 12-week timepoints
  • Positive outcomes sustained at 12 weeks including a 73% reduction in weekly binge-eating episodes, demonstrating durability of treatment response
  • Human Research Ethics Committee approval secured for a 72-patient, eight-indication Phase 1b/2a basket study, significantly expanding TRP-8803's development pipeline ahead of potential Phase 3 trials
  • Strategic GMP Manufacturing agreement signed with BioCina, establishing pharmaceutical-grade production capability for TRP-8803

A Clinical Signal That Stands Out

Entropy Neurodynamics Limited (ASX:ENP) reported clinical data from its TRP-8803 Phase 2 program during the September 2026 quarter that, by the standards of any therapeutic category, represents an unusually clear signal of efficacy.

The company's intravenous-infused psilocin candidate, TRP-8803, was studied in patients with treatment-resistant Binge Eating Disorder — a neuropsychiatric condition with limited approved pharmacological treatment Options and significant unmet medical need. The results from the Phase 2 study showed 100% of patients achieving clinically meaningful improvement, with 50% achieving complete remission at both four- and 12-week follow-up timepoints.

The 12-week outcome is particularly important. It includes a 73% reduction in weekly binge-eating episodes, a sustained effect that addresses one of the central challenges in neuropsychiatric drug development: durability. Many treatments produce early-stage responses that attenuate over time, so a maintained effect at three months is a clinically meaningful finding.

The Basket Study: Eight Indications, One Platform

Building on the BED results, Entropy secured Human Research Ethics Committee approval during the quarter for a significantly expanded clinical program. The approved 72-patient, eight-indication Phase 1b/2a basket study represents a strategic move to demonstrate TRP-8803's potential across multiple neuropsychiatric disorders using a single study design.

Basket studies are an efficient regulatory and clinical strategy: rather than running parallel, indication-specific trials, a single study with multiple arms provides early-stage data on multiple disease areas simultaneously. For a company at Entropy's stage, this approach maximises the data output from a fixed Capital base while building the clinical narrative for potential Phase 3 partnerships or out-licensing discussions.

The eight-indication scope signals that Entropy — and its scientific advisors — believe TRP-8803's mechanism of action is applicable across a broader spectrum of neuropsychiatric conditions than binge eating disorder alone.

Manufacturing Capability Established

The strategic agreement with BioCina for GMP (Good Manufacturing Practice) manufacture of TRP-8803 is an operationally significant milestone. Pharmaceutical-grade manufacturing capability is a prerequisite for regulatory submissions and late-stage clinical trials, and establishing this capability with an established contract manufacturer reduces one of the key execution risks for the company's development program.

This agreement, combined with the HREC approval for the basket study, indicates Entropy is positioning itself to move from single-indication Phase 2 results to a multi-indication Phase 1b/2a program with the manufacturing infrastructure in place to support it.

The Psychedelic Therapeutics Landscape

TRP-8803's development sits within the rapidly evolving field of psychedelic-assisted therapy, which has attracted substantial clinical research interest following decades of limited investigation. Psilocin — the active metabolite of psilocybin — has demonstrated efficacy signals in depression, post-traumatic stress disorder, and eating disorders across several academic and company-sponsored trials globally.

Entropy's differentiation lies in its precision-controlled IV delivery format, which allows dosing to be titrated and terminated in real time, unlike oral formulations where plasma concentrations follow a fixed absorption and elimination curve. This control profile may have regulatory and safety advantages that could differentiate TRP-8803 from orally-administered competitors.

Risks

Clinical-stage biotech companies carry inherent development risk. The Phase 2 BED results, while highly encouraging, were from a small patient population. Larger Phase 3 trials will need to replicate these outcomes in statistically powered patient cohorts with placebo-controlled designs to satisfy regulatory requirements. The basket study, while efficient in design, will generate early-phase data rather than pivotal-trial evidence.

Regulatory pathways for psychedelic therapeutics are still evolving in most markets, including Australia, creating some uncertainty around approval timelines and requirements.

What to Watch Next

The initiation of the 72-patient basket study and any interim data readouts will be key catalysts for Entropy over the coming quarters. Investors should also watch for any announcement of pharmaceutical partnerships or licensing discussions that may follow from the BED data and the broader multi-indication program. Progress on BioCina's GMP manufacturing ramp-up will also be relevant to the company's clinical timelines.

Sector Context

The neuropsychiatric Drug Development sector — and specifically the psychedelic therapeutics segment — has attracted significant capital and scientific attention through 2025 and 2026. Several companies globally have advanced psychedelic compounds into Phase 2 and Phase 3 trials for treatment-resistant depression and PTSD, and the clinical community is increasingly recognising the durability of responses observed in these trials. Entropy's BED data adds to this growing body of evidence and positions TRP-8803 as a platform candidate rather than a single-indication compound.